Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.

International journal of radiation oncology, biology, physics - 1 Nov 2011

Kim Sun Young, Hong Yong Sang, Kim Dae Yong, Kim Tae Won, Kim Jee Hyun, Im Seok Ah, Lee Keun Seok, Yun Tak, Jeong Seung-Yong, Choi Hyo Seong, Lim Seok-Byung, Chang Hee Jin, Jung Kyung Hae

Abstract excerpt

PURPOSE: To evaluate the efficacy and safety of preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with rectal cancer. METHODS AND MATERIALS: Forty patients with locally advanced, nonmetastatic, and mid- to lower rectal cancer were enrolled. Radiotherapy was delivered at a dose of 50.4 Gy/28 fractions. Concurrent chemotherapy consisted of an initial dose of cetuximab of 400...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Capecitabine
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Deoxycytidine

Share to Irinotecan

Share to Preoperative Care

Share to Radiotherapy Dosage

Share to Rectal Neoplasms

Source

Identifiers

PMID: 20888703
DOI: 10.1016/j.ijrobp.2010.06.035

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.PMID 20888703Read ↗

Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.Semantic proximity Read ↗

KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.Semantic proximity Read ↗

Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).Semantic proximity Read ↗

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).Semantic proximity Read ↗

Neoadjuvant Combination Immunotherapy for Colorectal Cancer: Clinical and Molecular Predictors of Pathological Complete Response and Safety AssessmentSemantic proximity Read ↗

A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis.Semantic proximity Read ↗

Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: A case report and literature review.Semantic proximity Read ↗

Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer.Semantic proximity Read ↗

Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety.Semantic proximity Read ↗

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.Semantic proximity Read ↗

KRAS Mutant Status May Be Associated with Distant Recurrence in Early-stage Rectal Cancer.Semantic proximity Read ↗

KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.